MannKind | MNKD - Sales Revenues


MannKind reported $82.13M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Adma Biologics USD 134.22M 12.24M Sep/2025
BioCryst Pharmaceuticals USD -86.95M 204.03M Dec/2024
Eli Lilly USD 19.3B 1.7B Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
MacroGenics USD 72.84M 50.6M Sep/2025
MannKind USD 82.13M 5.6M Sep/2025
Merck USD 16.4B 880M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 84.51M 330.97M Sep/2024
Novo Nordisk DKK 12.53B 560M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Xencor USD 28.24M 7.24M Dec/2025